Table 2.

Overall AEs in participants ≥60 years of age with ≥5% incidence in any treatment group

AEs, n (%)	Quarterly fremanezumab (n = 74)	Monthly fremanezumab (n = 92)	Placebo (n = 80)
Any AE	48 (65)	53 (58)	44 (55)
SAEs	2 (3)	3 (3)	2 (3)
AEs leading to discontinuation	1 (1)	1 (1)	2 (3)
Most common AEs (incidence ≥5% in any treatment group)
Injection-site induration	11 (15)	23 (25)	14 (18)
Injection-site pain	13 (18)	19 (21)	10 (13)
Injection-site erythema	8 (11)	10 (11)	13 (16)
Nasopharyngitis	4 (5)	5 (5)	4 (5)

AE, adverse event; SAE, serious adverse event